Table 3:

CYP3A4 – Modulators – adopted from^{13, 56, 163–165}

CYP450 3A4 Modulator
Inhibitor		Inducer
Strong Inhibitor	Boceprevir	Strong Inducer	Apalutamide
	Ceritinib		Carbamazepine
	Clarithromycin* although a strong inhibitor of both 3A4 and P-gp, pharmacokinetic data suggests concomitant use with a DOAC is safe (labels)		Enzalutamide
	Cobicistat		Mitotane
	Grapefruit Juice		Phenytoin
	Idelalisib		Rifampin
	Indinavir		St. John's wort
	Itraconazole
	Ketoconazole	Moderate Inducer	Bosentan
	Nefazodone		Efavirenz
	Nelfinavir		Etravirine
	Posaconazole		Phenobarbital
	Ribociclib		Primidone
	Ritonavir
	Saquinavir	Weak Inducer	Armodafinil
	Telaprevir		Modafinil
	Tucatinib		Rufinamide
	Voriconzole
		Undetermined	Aminoglutethimide
			Bexarotene
Moderate Inhibitor	Aprepitant		Brigatinib
	Ciprofloxacin		Dabrafenib
	Conivaptan		Dexamethasone
	Crizotinib		Dicloxacillin
	Cyclosporine		Eslicarbazepine
	Diltiazem		Fosphenytoin
	Dronedarone		Griseofulvin
	Erythromycin		Lesinurad
	Fluconazole		Lumacaftor
	Fluvoxamine		Nafcillin
	Grapefruit		Nevirapine
	Imatinib		Rifabutin
	Netupitant and Palonostrone (Akynzeo®)		Rifapentine
	Verapamil		Sarilumab
			Telotristat
Weak Inhibitor	Amiodarone		Tocilizumab
	Atomoxetine		Troglitazone
	Chlorzoxazone		Vemurafenib
	Cilostazol		Vinblastine
	Clotrimazole
	Entrectinib
	Esomeprazole
	Fosaprepitant
	Istradefylline
	Ivcaftor
	Lomitapide
	Omeprazole
	Quercetin
	Ranitidine
	Ranolazine
	Simeprevir
	Ticagrelor
Undetermined	Amprenavir
	Atazanavir
	Berberine
	Chloramphenicol
	Dalfoprestin
	Danazol
	Darunavir
	Dasatinib
	Delavirdine
	Dexmedetomidine
	Ethinyl Estradiol
	Fosaprenavir
	Isavuconazonium
	Isoniazid
	Lapatinib
	Larotrectinib
	Letermovir
	Miconazole
	Mifepristone
	Netupitant
	Palbociclib
	Quinupristin (Synercid)
	Simeprevir
	Stiripentol
	Tamoxifen
	Voxilaprevir